Trial Profile
A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 May 2017
Price :
$35
*
At a glance
- Drugs Mitoxantrone liposomal (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 23 May 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2017.
- 23 May 2017 Status changed from recruiting to discontinued.
- 13 Nov 2015 New trial record